转变小细胞肺癌的分子机制和临床见解:叙事性综述
Xianzi Dai1, Yue Hao2, Jiaojiao Hong1
1Department of Respiratory Medicine, Jiangsu Province Hospital of Chinese Medicine (Affiliated Hospital of Nanjing University of Chinese Medicine), Nanjing, China.
从非小细胞肺癌转变为小细胞肺癌 (SCLC) 的组织学转变是一种抵抗机制. 识别转化SCLC (T-SCLC) 的分子生物标志物可以优化治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 向疗法可以改善驱动基因阳性非小细胞肺癌 (NSCLC) 的存活率.
- 获得的耐药性可以表现为从NSCLC到小细胞肺癌 (SCLC) 的组织学转变.
- 这种转变称为T-SCLC,在向和非向治疗中发生,需要了解其机制.
研究的目的:
- 识别能够预测NSCLC转化为SCLC的关键分子生物标志物.
- 优化转型SCLC (T-SCLC) 的临床管理策略.
主要方法:
- 在PubMed,EMBASE,Cochrane图书馆和会议记录中进行系统的文献搜索,截至2024年12月31日.
- 对T-SCLC转变机制,基因组/转录基因组改变和治疗方法的当前证据的综合.
主要成果:
- T-SCLC转变涉及瘤异质性和血统可塑性.
- 关键的分子参与者包括PI3K/AKT/mTOR,NOTCH-ASCL1,SMAD4,SOX2和表观遗传异常.
- TP53和RB1无活化可能是预测生物标志物;化疗+/-EGFR-TKI是当前的治疗方法.
结论:
- 由于研究的局限性 (回顾性,小样本),T-SCLC机制尚未完全理解.
- 肺癌的可塑性和血统可塑性驱动了这种抵抗机制.
- 基于分子分析的个性化疗法是改善结果的未来方向.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation
